SCHEMBL20565459

SCHEMBL20565459

N#Cc1c(-c2ccc(Cl)cc2Cl)nn2c(=O)c3ccccc3[nH]c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.49
EGFR P00533 1/20 0.49
CDK4 P11802 1/20 0.49
BRAF P15056 1/20 0.49
CDK6 Q00534 1/20 0.49
KDM4E B2RXH2 5/20 0.46
HTT P42858 1/20 0.46
HPGD P15428 2/20 0.43
USP2 O75604 1/20 0.43
POLB P06746 1/20 0.43
ALOX12 P18054 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
GAA P10253 2/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20565509 0.91 HPGD (0.45) METEGFRCDK4BRAFCDK6
SCHEMBL20565557 0.85 MET (0.45) METEGFRCDK4BRAFCDK6
SCHEMBL20565140 0.83 KDM4E (0.42) METEGFRCDK4BRAFCDK6
SCHEMBL20565512 0.83 KDM4E (0.51) METEGFRCDK4BRAFCDK6
SCHEMBL20565458 0.82 AS3MT (0.49) CNR1
SCHEMBL20565109 0.82 DYRK1A (0.42) METEGFRCDK4BRAFCDK6
SCHEMBL20564460 0.82 DYRK1A (0.40) METEGFRCDK4BRAFCDK6
SCHEMBL20565588 0.81 KDM4E (0.46) METEGFRCDK4BRAFCDK6
SCHEMBL20565517 0.80 KDM4E (0.46) KDM4EHTTMEN1KMT2ANPC1
SCHEMBL23635353 0.80 MET (0.45) METEGFRCDK4BRAFCDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11192893-B2 Pyrazoloquinazolinone antitumor agents THE ROCKEFELLER UNIVERSITY (US) 2021-12-07 US disclosed
US-11192893-B2 Pyrazoloquinazolinone antitumor agents THE ROCKEFELLER UNIVERSITY (US) 2021-12-07 US disclosed
US-20200148687-A1 PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS THE ROCKEFELLER UNIVERSITY (US) 2020-05-14 US disclosed
US-20200148687-A1 PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS THE ROCKEFELLER UNIVERSITY (US) 2020-05-14 US disclosed
EP-3624805-A1 PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS Kapoor, Tarun, M. (US) 2020-03-25 EP disclosed
WO-2018213712-A1 PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS KAPOOR TARUN M (US) 2018-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148687-A1 PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 MET 1997/4885EGFR 1423/4885CDK4 741/4885
US-11192893-B2 Pyrazoloquinazolinone antitumor agents H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 MET 1997/4885EGFR 1423/4885CDK4 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.